Article in JNCI cancer spectrum, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
27 authors at 11 institutions in 3 countries.
Rebecca D KehmDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.ORCID 0000-0002-6089-6799
Robert J MacInnisCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.ORCID 0000-0002-1627-5047
Esther M JohnDepartment of Medicine and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0003-3259-8003
Yuyan LiaoDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
Allison W KurianDivision of Medical Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-6175-9470
Jeanine M GenkingerDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.ORCID 0000-0002-8438-0412
Julia A KnightLunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
Sarah V ColonnaDivision of Medical Oncology, Huntsman Cancer Institute, Salt Lake City, UT, USA.ORCID 0000-0002-9026-6990
Wendy K ChungHerbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA.ORCID 0000-0003-3438-5685
Roger MilneCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.ORCID 0000-0001-5764-7268
Nur ZeinomarCancer Epidemiology and Health Outcomes, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ, USA.ORCID 0000-0001-8219-8599
Gillian S DiteCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.ORCID 0000-0002-2448-2548
Melissa C SoutheyCancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.ORCID 0000-0002-6313-9005
Graham G GilesCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.ORCID 0000-0003-4946-9099
Sue-Anne McLachlanDepartment of Medicine, St Vincent's Hospital, The University of Melbourne, Melbourne, Victoria, Australia.ORCID 0000-0002-1072-0322
Kristen D WhitakerDepartment of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, USA.ORCID 0000-0002-8084-3838
Michael L FriedlanderPrince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia.ORCID 0000-0003-3090-795X
Prue C WeidemanCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.
Gord GlendonLunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.ORCID 0000-0001-8630-6673
Stephanie NesciDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
kConFab Investigators
Kelly-Anne PhillipsCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.ORCID 0000-0002-0475-1771
Irene L AndrulisLunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.ORCID 0000-0002-4226-6435
Saundra S BuysDepartment of Medicine and Huntsman Cancer Institute, University of Utah Health, Salt Lake City, UT, USA.ORCID 0000-0003-4120-5697
Mary B DalyDepartment of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, USA.
John L HopperCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.ORCID 0000-0002-8567-173X
Mary Beth TerryDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.ORCID 0000-0002-4106-5033
The University of Melbourne · AUColumbia University Irving Medical Center · USFox Chase Cancer Center · USColumbia University · USStanford University · USUniversity of Toronto · CAHuntsman Cancer Institute · USLunenfeld-Tanenbaum Research Institute · CAPeter MacCallum Cancer Centre · AURutgers, The State University of New Jersey · USUNSW Sydney · AU
Funding
Core-001U01CA164920 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Irene Andrulis, Sarah Violet Colonna · 2018 to 2026
$17.0M
Genes, environment and breast cancer risk: The 15 year follow-up of the Prof-SC (Diversity Supplement)R01CA159868 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HOPPER, JOHN L, TERRY, MARY BETH · 2011 to 2015
$9.0M
NCI NIH HHS R01 CA159868NCI NIH HHS U01 CA164920
6 · The paper itself
Abstract
Background: Recreational physical activity (RPA) is associated with improved survival after breast cancer (BC) in average-risk women, but evidence is limited for women who are at increased familial risk because of a BC family history or Methods: We estimated associations of RPA (self-reported average hours per week within 3 years of BC diagnosis) with all-cause mortality and second BC events (recurrence or new primary) after first invasive BC in women in the Prospective Family Study Cohort (n = 4610, diagnosed 1993-2011, aged 22-79 years at diagnosis). We fitted Cox proportional hazards regression models adjusted for age at diagnosis, demographics, and lifestyle factors. We tested for multiplicative interactions (Wald test statistic for cross-product terms) and additive interactions (relative excess risk due to interaction) by age at diagnosis, body mass index, estrogen receptor status, stage at diagnosis, Results: We observed 1212 deaths and 473 second BC events over a median follow-up from study enrollment of 11.0 and 10.5 years, respectively. After adjusting for covariates, RPA (any vs none) was associated with lower all-cause mortality of 16.1% (95% confidence interval [CI] = 2.4% to 27.9%) overall, 11.8% (95% CI = -3.6% to 24.9%) in women without Conclusion: Findings support that RPA is associated with lower all-cause mortality in women with BC, particularly in women with
Indexed as
ExerciseGenetic Predisposition to DiseaseRecreation TherapyAdultAgedAge FactorsBreast NeoplasmsCause of DeathFemaleFollow-Up StudiesGenes, BRCA1Genes, BRCA2HumansMiddle AgedNeoplasm Recurrence, LocalNeoplasms, Second Primary
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk. · full record | OpenQuestion